Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the resubmission of the New Drug Application (NDA)
for sugammadex sodium injection has been accepted for review by the U.S.
Food and Drug Administration (FDA). Merck expects the FDA’s review to be
completed in the first half of 2013.
Language:
English
Contact HTML:
MerckMedia Contacts:Pam Eisele, 908-423-5042Lainie Keller, 908-423-4187orInvestor Contact:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Source Type: news